Hoi A - Search Results

1

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus.

Koelmeyer R, Nim HT, Nikpour M, Sun YB, Kao A, Guenther O, Morand E, Hoi A. Koelmeyer R, et al. Among authors: hoi a. Lupus Sci Med. 2020 May;7(1):e000372. doi: 10.1136/lupus-2019-000372. Lupus Sci Med. 2020. PMID: 32467293 Free PMC article.

2

The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation.

Gordon RA, Nguyen Y, Foulquier N, Beydon M, Gheita TA, Hajji R, Sahbudin I, Hoi A, Ng WF, Mendonça JA, Wallace DJ, Shea B, Bruyn GA, Goodman SM, Fisher BA, Baldini C, Torralba KD, Bootsma H, Akpek EK, Karakus S, Baer AN, Chakravarty SD, Terslev L, D'Agostino MA, Mariette X, DiRenzo D, Rasmussen A, Papas A, Montoya C, Arends S, Yusof MYM, Pintilie I, Warner BM, Hammitt KM, Strand V, Bouillot C, Tugwell P, Inanc N, Andreu JL, Wahren-Herlenius M, Devauchelle-Pensec V, Shiboski CH, Benyoussef A, Masli S, Lee AYS, Cornec D, Bowman S, Rischmueller M, McCoy SS, Seror R. Gordon RA, et al. Among authors: hoi a. Semin Arthritis Rheum. 2024 Apr;65:152378. doi: 10.1016/j.semarthrit.2024.152378. Epub 2024 Jan 23. Semin Arthritis Rheum. 2024. PMID: 38310657

3

Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis.

Hoi AY, Morand EF. Hoi AY, et al. Rheumatology (Oxford). 2003 Feb;42(2):390-1. doi: 10.1093/rheumatology/keg067. Rheumatology (Oxford). 2003. PMID: 12595649 No abstract available.

4

Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?

Hoi AY, Morand EF, Leech M. Hoi AY, et al. Immunol Cell Biol. 2003 Oct;81(5):367-73. doi: 10.1046/j.1440-1711.2003.01183.x. Immunol Cell Biol. 2003. PMID: 12969324 Review.

5

Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice.

Hoi AY, Hickey MJ, Hall P, Yamana J, O'Sullivan KM, Santos LL, James WG, Kitching AR, Morand EF. Hoi AY, et al. J Immunol. 2006 Oct 15;177(8):5687-96. doi: 10.4049/jimmunol.177.8.5687. J Immunol. 2006. PMID: 17015758

6

Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases.

Hoi AY, Iskander MN, Morand EF. Hoi AY, et al. Inflamm Allergy Drug Targets. 2007 Sep;6(3):183-90. doi: 10.2174/187152807781696455. Inflamm Allergy Drug Targets. 2007. PMID: 17897055 Review.

7

Smooth muscle myopathy as an underrecognized manifestation of active systemic lupus erythematosus.

Ngian GS, Naidoo P, Morand EF, Hoi AY. Ngian GS, et al. Among authors: hoi ay. Intern Med J. 2011 Jun;41(6):495-8. doi: 10.1111/j.1445-5994.2011.02505.x. Intern Med J. 2011. PMID: 21707895

8

Lymphocytes from systemic lupus erythematosus patients display increased spreading on VCAM-1, an effect associated with active renal involvement.

Cheng Q, Hoi A, Hickey MJ, Morand EF. Cheng Q, et al. Among authors: hoi a. Lupus. 2012 May;21(6):632-41. doi: 10.1177/0961203312436860. Epub 2012 Feb 16. Lupus. 2012. PMID: 22345121

9

Abatacept in the treatment of lupus.

Hoi AY, Littlejohn GO. Hoi AY, et al. Expert Opin Biol Ther. 2012 Oct;12(10):1399-406. doi: 10.1517/14712598.2012.713934. Epub 2012 Aug 7. Expert Opin Biol Ther. 2012. PMID: 22870890

10

Asian ethnicity in systemic lupus erythematosus: an Australian perspective.

Connelly K, Morand EF, Hoi AY. Connelly K, et al. Among authors: hoi ay. Intern Med J. 2013 Jun;43(6):618-24. doi: 10.1111/imj.12070. Intern Med J. 2013. PMID: 23279565 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Search Page

Filters